Evidence map›Paper›PMID 41174101›Full record

ArticleScientific reports2025

Design of a single particle-interferometric reflectance imaging sensor adipo-chip for obesity biomarker screening.

N Lago-Baameiro, T Camino, A Estévez-López, A Vázquez-Durán, M Fernández-Nogueira, A Sueiro, F Santos, J Baltar, M Pardo

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

N Lago-BaameiroLaboratorio 3, Grupo Obesidómica, Área de Endocrinología, Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Complexo Hospitalario Universitario de Santiago de Compostela/SERGAS, Travesía da Choupana s/n, 15706, Santiago de Compostela, A Coruña, Spain.
T CaminoLaboratorio 3, Grupo Obesidómica, Área de Endocrinología, Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Complexo Hospitalario Universitario de Santiago de Compostela/SERGAS, Travesía da Choupana s/n, 15706, Santiago de Compostela, A Coruña, Spain.
A Estévez-LópezLaboratorio 3, Grupo Obesidómica, Área de Endocrinología, Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Complexo Hospitalario Universitario de Santiago de Compostela/SERGAS, Travesía da Choupana s/n, 15706, Santiago de Compostela, A Coruña, Spain.
A Vázquez-DuránLaboratorio 3, Grupo Obesidómica, Área de Endocrinología, Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Complexo Hospitalario Universitario de Santiago de Compostela/SERGAS, Travesía da Choupana s/n, 15706, Santiago de Compostela, A Coruña, Spain.
M Fernández-NogueiraLaboratorio 3, Grupo Obesidómica, Área de Endocrinología, Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Complexo Hospitalario Universitario de Santiago de Compostela/SERGAS, Travesía da Choupana s/n, 15706, Santiago de Compostela, A Coruña, Spain.
A SueiroGrupo Endocrinología Molecular y Celular, Instituto de Investigación Sanitaria de Santiago (IDIS), Complexo Hospitalario Universitario de Santiago de Compostela/SERGAS, Santiago de Compostela, Spain.
F SantosLaboratorio 3, Grupo Obesidómica, Área de Endocrinología, Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Complexo Hospitalario Universitario de Santiago de Compostela/SERGAS, Travesía da Choupana s/n, 15706, Santiago de Compostela, A Coruña, Spain.
J BaltarLaboratorio 3, Grupo Obesidómica, Área de Endocrinología, Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Complexo Hospitalario Universitario de Santiago de Compostela/SERGAS, Travesía da Choupana s/n, 15706, Santiago de Compostela, A Coruña, Spain.
M PardoLaboratorio 3, Grupo Obesidómica, Área de Endocrinología, Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Complexo Hospitalario Universitario de Santiago de Compostela/SERGAS, Travesía da Choupana s/n, 15706, Santiago de Compostela, A Coruña, Spain. maruxapardo@hotmail.com.

Funding

Axencia Galega de Innovación Axudas predoutoraisMinisterio de Educación, Cultura y Deporte FPU program
6 · The paper itself

Abstract

In light of the obesity pandemic, there is an increasing imperative to identify obesity phenotypes that encompass factors such as adipose tissue distribution, inflammation, and insulin sensitivity, to devise tailored therapeutic strategies. Within this context, extracellular vesicles (EVs) have emerged as promising reservoirs of biomarkers. However, the inherent technical challenges associated with their isolation and analysis necessitate the development of precise, high-throughput technologies to facilitate their integration into clinical settings. The single-particle interferometric reflectance imaging sensor (SP-IRIS) has emerged as a valuable tool that enables the analysis of biomarkers in individual EVs without the need for prior purification. The fundamental principle of SP-IRIS involves the capture of EVs using functionalized chips with capture antibodies targeting standard exosomal tetraspanins, with the option of employing custom antibodies to capture cell- or tissue-specific EVs. Herein, we describe, for the first time, the design and validation of an SP-IRIS chip functionalized with two capture antibodies to assess adipose-specific (adipo-chip) secreted vesicles for biomarker assessment. Using this approach, we demonstrate that the designed adipo-chip captures EVs directly secreted by the whole adipose tissue of patients with obesity undergoing bariatric surgery, allowing the quantification of up to four previously described adipose EV-biomarkers. Thus, we demonstrate for the first time the capacity of the adipo-chip to enrich the capture of adipose-secreted EVs, enabling the detection of changes in described biomarkers with potential applications in clinical settings through liquid biopsy at the circulating level.

Indexed as

Adipose TissueBiomarkersBiosensing TechniquesExtracellular VesiclesInterferometryObesityFemaleHumansBiomarkersAdipose tissueBiomarkersExtracellular vesiclesObesitySP-IRIS

Identifiers

PMID41174101
PMCPMC12578844

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.